US Oncology Archives

TGen-TD2-Scottsdale Healthcare study benefits patients


The Side-Out Foundation’s breast cancer pilot study, led by the Translational Genomics Research Institute (TGen), Translational Drug Development (TD2) and Scottsdale Healthcare, has shown that cancer patients do better when their treatment is guided by molecular profiling. Specifically, 52 percent of patients with advanced breast cancer received clinical benefit – meaning their disease was controlled… Read More →

TGen-US Oncology data helps triple-negative breast cancer patients

by in Bioscience | Featured | Healthcare

Genomic sequencing has revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC), according to an unprecedented study by the Translational Genomic Research Institute (TGen) and US Oncology Research. The study is published by the journal Molecular Cancer Therapeutics and is currently available online. By sequencing, or spelling out, the billions of letters contained… Read More →